Related Experiment Video
Updated: Apr 7, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
Published on: August 1, 2025
Regramming myeloid responses to improve cancer immunotherapy
Yu Zhu1, William G Hawkins2, David G DeNardo3
1Department of Medicine; Washington University School of Medicine ; St. Louis, MO, USA ; Siteman Cancer Center; Washington University School of Medicine ; St. Louis, MO, USA ; ICCE Institute; Washington University School of Medicine ; St. Louis, MO, USA.
Abstract:
Infiltration by immunosuppressive myeloid cells helps tumors to overcome immune surveillance and can render patients less responsive to therapeutic intervention. Several recent studies have demonstrated that reprogramming myeloid responses can effectively enhance cancer immunotherapy, suggesting several new potential combination therapies for clinical testing.
Related Concept Videos
Tumor Immunotherapy
Differentiation of Common Myeloid Progenitor Cells
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Somatic to iPS Cell Reprogramming

